We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is ... NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Show more
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass., April 17, 2024 Phase 1 Clinical Trial...
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire CAMBRIDGE, Mass., April 1, 2024 Full Data Readout...
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., March 28, 2024 Received First Site Institutional Review Board (IRB...
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire CAMBRIDGE, Mass., March 13...
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer PR Newswire CAMBRIDGE, Mass., March 4, 2024 CAMBRIDGE, Mass., March 4, 2024...
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass., Feb. 29, 2024 First Patient...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.45 | -12.8571428571 | 3.5 | 3.69 | 3.08 | 18229 | 3.33894102 | CS |
4 | -1.33 | -30.3652968037 | 4.38 | 4.57 | 3.08 | 28967 | 3.80260779 | CS |
12 | -0.34 | -10.0294985251 | 3.39 | 6.7499 | 3.08 | 1436965 | 5.42753371 | CS |
26 | -0.47 | -13.3522727273 | 3.52 | 6.7499 | 2.9 | 709114 | 5.3177622 | CS |
52 | -2.4796 | -44.8423032407 | 5.5296 | 6.7499 | 2.8888 | 499913 | 5.01152064 | CS |
156 | -829.75 | -99.63376561 | 832.8 | 1576.8 | 2.8888 | 1038996 | 260.41331789 | CS |
260 | -2192.95 | -99.8611111111 | 2196 | 7200 | 2.8888 | 755328 | 321.7709478 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions